Zheng Quan Ri Bao·2025-12-07 10:12Core Points - The 2025 National Medical Insurance Drug List was officially announced in Guangzhou on December 7, 2023, including the addition of the BTK inhibitor Ibrutinib (brand name: Aobutini) for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients [2] - Aobutini also successfully renewed its indications for previously treated CLL/SLL, Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL) [2] - The new drug list will be implemented starting January 1, 2026, and was released during the 2025 Innovative Drug High-Quality Development Conference [2] Company Highlights - Aobutini was approved for the first-line treatment of CLL/SLL patients in April 2023, marking its fourth indication in China [3] - As a result of the "Major New Drug Creation" initiative, Aobutini has nearly 100% target selectivity for the BTK target, with minimal inter-individual variability and no significant inhibitory effects on other kinases, ensuring efficacy while avoiding adverse reactions due to off-target effects [3] - Aobutini offers the convenience of once-daily oral administration, facilitating continuous treatment for patients [3]